# A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

> **NCT01004224** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 208 (actual)

## Conditions studied

- Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3
- Squamous Lung Cancer With FGFR1 Amplification
- Bladder Cancer With FGFR3 Mutation or Fusion
- Advanced Solid Tumors With FGFR1 Amplication
- Advanced Solid Tumors With FGFR2 Amplication
- Advanced Solid Tumors With FGFR3 Mutation

## Interventions

- **DRUG:** BGJ398

## Key facts

- **NCT ID:** NCT01004224
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12-11
- **Primary completion:** 2018-10-08
- **Final completion:** 2018-10-08
- **Target enrollment:** 208 (ACTUAL)
- **Last updated:** 2019-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01004224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01004224, "A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01004224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*